Vanda Pharmaceuticals Inc. (VNDA) fair value analysis
Nasdaq · Updated 2026-10-19
VNDA price how computed
Valuation status
No verdict this weekVNDA: Next year's consensus is far above both what this company earned over the last four quarters and what its most recent quarter is earning.
Our model does not publish a verdict on a forecast that far from results; it is re-evaluated weekly.
- Last price
- $4.03
- Sector
- Healthcare
- 12-month range
- $4.03–$9.56
- Market cap
- $244M
- From 52-week high
- -57.8%
- Shares outstanding
- 60.5M
- Rank in Healthcare by quality score
- #139 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes prescription medications for central nervous system disorders and other therapeutic areas. The company operates primarily in the United States and maintains operations to support its product development and marketing activities across multiple markets.
VNDA currently ranks #139 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $244M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $216M
- Net margin
- -127.4%
- EPS (TTM)
- $-4.63
- Gross margin
- 93.0%
- Debt / equity
- 0.10
- Revenue growth (3-yr avg)
- 10.1%
- Shares outstanding
- 60.5M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 19 · oversold
- 50-day average
- $5.03
- 200-day average
- $6.41
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-103.9%)
2026-03 ▼ miss (-18.8%)
2025-12 ▼ miss (-81.1%)
2025-09 ▲ beat (+15.6%)
2025-06 ▼ miss (-27.8%)
2025-03 ▲ beat (+16.7%)
2024-12 ▲ beat (+27.3%)
2024-09 ▲ beat (+43.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 1 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $11.8
- Target vs last price
- +192.8%
What our data shows for VNDA
- Our model validated 7 trailing price-to-earnings windows for VNDA, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $4.03–$9.56.
- The 14-day relative strength index sits at an oversold 19.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- VNDA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent VNDA news
TickrTrends' derived news-sentiment signal for VNDA is currently mixed, computed from recent coverage.
- Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches (NASDAQ:VNDA) (seekingalpha.com, 2026-10-15)
TickrTrends take: Vanda Pharmaceuticals operates in the Healthcare sector and is currently assessed as undervalued by TickrTrends, yet the company faces a significant operational constraint as its cash reserves are depleting at a rate faster than its product launches can generate offsetting revenue. For valuation-focused investors, this cash burn dynamic represents a critical monitoring point, as the timeline to cash depletion could materially impact the company's ability to fund operations and bring new products to market. The gap between cash consumption and commercial success of recent launches will likely become the determining factor in whether the undervalued assessment holds or represents a value trap. - Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phase III Anxiety Drug Trial Misses Endpoints (gurufocus.com, 2026-10-15)
TickrTrends take: Vanda Pharmaceuticals faced negative momentum in premarket trading following its Phase III trial setback for an anxiety treatment, which represents a meaningful near-term headwind for a clinical-stage program. Despite this clinical disappointment, TickrTrends currently assesses VNDA as undervalued, suggesting the market reaction may have overcorrected relative to the company's broader asset portfolio and pipeline prospects. Investors focused on valuation metrics should monitor whether the company's existing marketed products and remaining pipeline candidates can offset the lost revenue potential from this failed program and support near-term financial performance. - MILLENNIUM MANAGEMENT LLC Adds to Vanda Pharmaceuticals Inc (VNDA) Position -- Shares Look 25% Undervalued on GF Value (gurufocus.com, 2026-10-15)
TickrTrends take: Millennium Management's recent accumulation of VNDA shares aligns with the current TickrTrends assessment that the stock trades below its intrinsic value in the Healthcare sector. The reported 25% undervaluation gap suggests there may be room for price appreciation if market conditions shift or company fundamentals strengthen, though investors should monitor whether the company's pipeline progress and revenue trends support sustained valuation gains. A valuation-focused reader should track quarterly earnings reports and any updates on Vanda's drug development progress to determine if the current discount persists or narrows over time.
More VNDA news
- Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It (NASDAQ:VNDA) (seekingalpha.com, 2026-10-01)
- Vanda Pharmaceuticals (VNDA) Reports Positive Phase III Results for HETLIOZ in DSWPD (gurufocus.com, 2026-09-30)
- VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target (gurufocus.com, 2026-09-23)
What people are saying
Follow the VNDA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — VNDA, a healthcare sector stock, showed shifts in its derived indicators this week. The relative strength index moved from neutral territory into oversold conditions, while the stock's sector discount ranking improved from number 25 to number 20, suggesting it is trading at a larger discount relative to other healthcare companies. The current valuation assessment indicates the stock is undervalued.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — VNDA's sector positioning has strengthened this week, with its discount rank among Healthcare stocks improving from number 35 to number 27. This advancement reflects a more favorable valuation relative to peers in the sector. The stock maintains an Undervalued verdict according to TickrTrends' derived indicators.
- 2026-09-28 — VNDA's sector discount rank improved this week, moving from #41 to #35 among Healthcare sector stocks, indicating a relative strengthening of its valuation position within the peer group. The stock maintains an undervalued designation according to TickrTrends' derived indicators.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is VNDA stock undervalued?
VNDA does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is VNDA's TickrTrends verdict?
VNDA is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does VNDA compare to other Healthcare stocks?
VNDA ranks #139 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is VNDA overbought or oversold?
VNDA's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does VNDA report earnings next?
VNDA's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does VNDA usually beat earnings estimates?
Over its last 8 reported quarters VNDA beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VNDA?
Of 5 analysts covering VNDA, 4 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $11.8 (+192.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.